Summary
TRP Health Policy has prepared a background brief regarding the status of the FDA’s efforts to implement the Biologics Price Competition and Innovation Act (BCPIA). The new brief includes information about draft and final guidance documents issued at the end of the Obama Administration and the status of the biosimilar case Amgen v. Sandoz, which will be heard by the Supreme Court next month.